NCT02081625已完成1 期
Exploratory Study of NS-065/NCNP-01 in Duchenne Muscular Dystrophy
National Center of Neurology and Psychiatry, Japan1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Safety and tolerability (adverse event and adverse drug reaction)
研究概览
简要总结
This study is designed to assess the safety, tolerability, efficacy and pharmacokinetics (PK) of NS-065/NCNP-01 in subjects diagnosed with Duchenne muscular dystrophy (DMD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 18 Years（Child, Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject with Duchenne muscular dystrophy eligible for enrolment in the study must meet all of the following criteria:
- •Has an out of frame deletion(s) that could be corrected by skipping exon 53 as confirmed by any of methodology at the time of visit
- •If not confirmed by any of methodology that evaluates the relative copy number of all exons (i.e. MLPA, CGH etc), must be confirmed through these techniques by the time of visit
- •DNA sequencing of exon 53 confirms that no DNA polymorphisms occur that could compromise duplex formation between NS-065/NCNP-01 and pre-mRNA.
- •There is confirmation of detection of dystrophin mRNA with skipping of exon 53 and dystrophin production after in vitro exposure of NS-065/NCNP-01 to subject-derived cells.
- •Male and >= 5 years and < 18 years of age at the time of obtaining informed consent and/or assent.
- •Able to give informed consent in writing signed by parent(s) or legal guardian who is able to understand all of the study procedure requirements. If applicable, able to give informed assent in writing signed by the subject.
- •Life expectancy of at least 1 year
- •Unable to ambulate. Ambulant subject can be enrolled according to the circumstances.
- •Have intact muscles, which have adequate quality for biopsy. (No lacks or severe atrophy of tibialis anterior muscle)
- •QTc <450 msec (based on 12-lead ECGs), or <480 msec for subject with Bundle Branch Block.
- •If taking glucocorticosteroids, no significant change in total daily dosage or dosing regimen after the time of visit 1.
排除标准
- •Subject with Duchenne muscular dystrophy meeting any of the following criteria must not be enrolled in the study:
- •Has participated in other pharmacological clinical trial that might recover dystrophin protein by the readthrough or the exon-skipping therapy, and/or upregulate the dystrophin-associated proteins such as utrophin.
- •A forced vital capacity (FVC) < 50% of predicted.
- •A left ventricular ejection fraction (EF) < 40% or fractional shortening (FS) < 25% based on echocardiogram (ECHO).
- •Surgery within the last 3 months prior to the first anticipated administration of study medication or planned for anytime during the duration of the study.
- •Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody test (HCV), or human immunodeficiency virus (HIV) test at screening.
- •Current diagnosis of any immune deficiency or autoimmune disease.
- •Current diagnosis of any active or uncontrolled infection, cardiomyopathy, or liver or renal disease.
- •Use of any other investigational agents and/or experimental agents within 3 months prior to the first anticipated administration of study medication.
- •History of any severe drug allergy.
- •Unable to give informed consent about using adequate contraception from the first administration until at least 6 months after the last dose of study medication, by parent(s) or legal guardian.
- •Subject considered by the investigator (or sub-investigator), for any reason, to be an unsuitable candidate for the study.
研究组 & 干预措施
NS-065/NCNP-01
Experimental
干预措施: NS-065/NCNP-01 (Drug)
结局指标
主要结局
Safety and tolerability (adverse event and adverse drug reaction)
时间窗: Up to 15-17 weeks (12 weeks treatment period and 3-5 weeks follow up period)
次要结局
- Expression of dystrophin protein(At 14-15 weeks (2-3 week after from 12 weeks treatment period))
- NS-065/NCNP-01 concentration of the blood plasma(12 weeks)
- NS-065/NCNP-01 concentration of the urine(12 weeks)
- Serum Creatine kinase concentration(14 weeks)
- Detection of exon53 skipped mRNA of dystrophin(At 14-15 weeks (2-3 week after from 12 weeks treatment period))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The clinical study of the safety and efficacy of docetaxel combined with ribavirin in docetaxel resistant castration resistant prostate cancerProstate cancerJPRN-UMIN000015130Keio University School of Medicine, Department of Urology20
招募中
不适用
A clinical study to investigate the efficacy of diuretics to the HF patients with proteinuria and edema.Heart FailureJPRN-UMIN000006212Social Insurance Yokohama Central Hospital15
已完成
不适用
A clinical study to evaluate to the effects of D-psicose (D-allulose) on respiratory metabolism (meal tolerance test)JPRN-UMIN000034213Soiken Inc.48
已完成
不适用
A clinical study to evaluate to the effects of D-psicose (D-allulose) on respiratory metabolism.Healthy volunteersJPRN-UMIN000033260Soiken Inc.48
尚未招募
Unknown
Effectiveness of Navak Guggulu on obesityCTRI/2023/03/051059Goverment Ayurvedic College, Patna